NCT06557304Not yet recruiting
The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China
This is a Multicenter, Retrospective Real-world Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China
Source: ClinicalTrials.gov · Last updated 21 Aug 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 13 Aug 2024
- Start date
- Sept 2024
- Primary completion date
- Sept 2026
- Lead sponsor
- Peking University People's Hospital
- Diseases
- Chronic lymphocytic leukaemia
- NCT number
- NCT06557304
What you commit to
- Study type: Observational
- Planned participants: 1000
- From Sept 2024 to the primary completion date, Sept 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Patients aged ≥18 years old
- Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL \[International Workshop on Chronic Lymphocytic Leukemia\] criteria)；
- Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on BTK inhibitor;
- Prior or current use of BTK inhibitor for ≥3 months
- At least one follow-up was recorded during BTK inhibitor treatment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.